CogState (CGS.AX) Stock Price
CogState Price
Over the last 19 years CogState grew revenue by 20.0% annually, reaching 53.09 M USD. Earnings per share have grown at 8.5% per year over the last 16 years. For CogState, the net margin of 19.1% is up versus 16.0% a few years ago. At today's price the dividend yield works out to roughly 1.12%. The payout ratio is around 34% of earnings. The consensus 12-month price target for CogState is 2.14 USD, about 15.8% below where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.
CogState stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
CogState business model & stock analysis
Frequently asked questions about CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analysts currently set an average price target of 2.14 USD for the CogState stock (median: 2.14 USD), implying -15.8 % versus the latest price. The consensus is based on 6 analyst ratings.
7 analysts currently rate the CogState stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CogState to generate revenue of 128.65 M USD and earnings per share of 0.09 USD.
Converted at the current exchange rate, the CogState share trades at 2.27 EUR (2.55 USD).
The CogState share (CGS.AX) is listed on 2 stock exchanges, including: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
The expected revenue of CogState is 128.65 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of CogState is 16.22 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of CogState is currently 27.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CogState stock.
The price-to-sales ratio (P/S) of CogState is currently 3.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CogState stock.
The Eulerpool Quality Score for CogState is 6/10.
The ISIN of CogState is AU000000CGS8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of CogState is CGS.AX. The ticker symbol is used to trade CogState shares on the stock exchange.
CogState stock
CogState Peer Group
CogState Ticker
CogState FIGI
All fundamentals and in-depth analysis of CogState
Our stock analysis for CogState stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CogState. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.